Vascular anomalies: From genetics toward models for therapeutic trials

Cold Spring Harbor Perspectives in Medicine

Volumn 2, Issue 8, 2012, Pages

  Uebelhoer, Melanie ^a   Boon, Laurence M ^a,b   Vikkula, Miikka ^a  

^a DE DUVE INSTITUTE   (Belgium)

^b CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ACEBUTOLOL; ACTIVIN RECEPTOR LIKE KINASE 1; ANGIOPOIETIN 1; ANGIOPOIETIN 2; ANGIOPOIETIN RECEPTOR; BEVACIZUMAB; CORTICOSTEROID; ENDOGLIN; FASUDIL; PROPRANOLOL; RAPAMYCIN; SIMVASTATIN; SMAD4 PROTEIN; SORAFENIB; TACROLIMUS; THALIDOMIDE; TRANSCRIPTION FACTOR FOXC2; TRANSCRIPTION FACTOR SOX18; VASCULOTROPIN RECEPTOR 3; VINCRISTINE;

ARTERIOVENOUS MALFORMATION; ARTICLE; CAPILLARY HEMANGIOMA; CAVERNOUS HEMANGIOMA; CONGENITAL BLOOD VESSEL MALFORMATION; DISEASE MODEL; GENE MUTATION; GENE TARGETING; GENE THERAPY; GLOMULIN GENE; GLOMUVENOUS MALFORMATION; HEREDITARY LYMPHEDEMA; HUMAN; HYPOTRICHOSIS LYMPHEDEMA TELANGIECTASIA; LOSS OF FUNCTION MUTATION; LYMPHATIC MALFORMATION; LYMPHEDEMA; MEIGE DISEASE; MILROY DISEASE; MISSENSE MUTATION; NEVUS FLAMMEUS; NONHUMAN; NUCLEIC ACID BASE SUBSTITUTION; PHENOTYPE; RENDU OSLER WEBER DISEASE; SCLEROTHERAPY; ANIMAL; CAPILLARY; CONGENITAL MALFORMATION; FEMALE; GENETICS; HEMANGIOMA; LYMPH NODE; MALE; MOUSE; MUTATION; REVIEW; SKIN TUMOR; SOFT TISSUE TUMOR;

ANIMALIA;

ANIMALS; CAPILLARIES; DISEASE MODELS, ANIMAL; FEMALE; HEMANGIOMA; HUMANS; LYMPH NODES; LYMPHEDEMA; MALE; MICE; MUTATION; SKIN NEOPLASMS; SOFT TISSUE NEOPLASMS; TELANGIECTASIA, HEREDITARY HEMORRHAGIC; VASCULAR MALFORMATIONS;

EID: 84879598902     PISSN: None     EISSN: 21571422     Source Type: Journal    
DOI: 10.1101/cshperspect.a009688     Document Type: Article

References (165)

1. Albiñana V, Bernabeu-Herrero ME, Zarrabeitia R, Bernabeu C, Botella LM. 2010. Estrogen therapy for hereditary haemorrhagic telangiectasia (HHT): Effects of raloxifene, on endoglin and ALK1 expression in endothelial cells. Thromb Haemost 103: 525-534.
2. Albiñana V, Sanz-Rodriguez F, Recio-Poveda L, Bernabéu C, Botella LM. 2011. Immunosuppressor FK506 increases endoglin and activin receptor-like kinase 1 expression and modulates transforming growth factor-β1 signaling in endothelial cells. Mol Pharmacol 79: 833-843.
3. Annabi B, Lachambre MP, Plouffe K, Moumdjian R, Beliveau R. 2009. Propranolol adrenergic blockade inhibits human brain endothelial cells tubulogenesis and matrix metalloproteinase-9 secretion. Pharmacol Res 60: 438-445.
4. Arai T, Kasper JS, Skaar JR, Ali SH, Takahashi C, DeCaprio JA. 2003. Targeted disruption of pp185/Cul7 gene results in abnormal vascular morphogenesis. Proc Natl Acad Sci 100: 9855-9860.
5. Au AC, Hernandez PA, Lieber E, Nadroo AM, Shen YM, Kelley KA, Gelb BD, DiazGA. 2010. Protein tyrosine phosphatase PTPN14 is a regulator of lymphatic function and choanal development in humans. Am J Hum Genet 87: 436-444.
6. Bayrak-Toydemir P, McDonald J, Akarsu N, Toydemir RM, Calderon F, TuncaliT, Tang W, Miller F, Mao R. 2006. A fourth locus for hereditary hemorrhagic telangiectasia maps to chromosome 7. Am J Med Genet A 140: 2155-2162.
7. Bell R, Brice G, Child AH, Murday VA, Mansour S, Sandy CJ, Collin JR, Brady AF, Callen DF, Burnand K, et al. 2001. Analysis of lymphoedema-distichiasis families for FOXC2 mutations reveals small insertions and deletions throughout the gene. Hum Genet 108: 546-551.
8. Bergametti F, Denier C, Labauge P, Arnoult M, Boetto S, Clanet M, Coubes P, Echenne B, Ibrahim R, Irthum B, et al. 2005. Mutations within the programmed cell death 10 gene cause cerebral cavernous malformations. Am J Hum Genet 76: 42-51.
9. Blei F, Walter J, Orlow SJ, Marchuk DA. 1998. Familial segregation of hemangiomas and vascular malformations as an autosomal dominant trait. Arch Dermatol 134: 718-722.
10. Boon LM, Vikkula M. 2008. Vascular malformations. In Fitzpatrick's dermatology in general medicine, 7th ed. (ed. Wolff K, et al.), Vol. 2, pp. 1651-1666. McGraw-Hill, New York.
11. Boon LM, Mulliken JB, Vikkula M, Watkins H, Seidman J, Olsen BR, Warman ML. 1994. Assignment of a locus for dominantly inherited venous malformations to chromosome 9p. Hum Mol Genet 3: 1583-1587.
12. Boon LM, MacDonald DM, Mulliken JB. 1999. Complications of systemic corticosteroid therapy for problematic hemangioma. Plast Reconstr Surg 104: 1616-1623.
13. Boon LM, Mulliken JB, Enjolras O, Vikkula M. 2004. Glomuvenous malformation (glomangioma) and venous malformation: Distinct clinicopathologic and genetic entities. Arch Dermatol 140: 971-976.
14. Boon LM, Mulliken JB, Vikkula M. 2005. RASA1: Variable phenotype with capillary and arteriovenous malformations. Curr Opin Genet Dev 15: 265-269.
15. Borikova AL, Dibble CF, Sciaky N, Welch CM, Abell AN, Bencharit S, JohnsonGL. 2010. Rho kinase inhibition rescues the endothelial cell cerebral cavernous malformation phenotype. J Biol Chem 285: 11760-11764.
16. Boscolo E, Bischoff J. 2009. Vasculogenesis in infantile hemangioma. Angiogenesis 12: 197-207.
17. Boulday G, Blecon A, Petit N, Chareyre F, Garcia LA, Niwa-Kawakita M, Giovannini M, Tournier-Lasserve E. 2009. Tissue-specific conditional CCM2 knockout mice establish the essential role of endothelial CCM2 in angiogenesis: Implications for human cerebral cavernous malformations. Dis Model Mech 2: 168-177.
18. Bourdeau A, Dumont DJ, Letarte M. 1999. A murine model of hereditary hemorrhagic telangiectasia. J Clin Invest 104: 1343-1351.
19. Breugem CC, Alders M, Salieb-Beugelaar GB, Mannens MM, Van der Horst CM, Hennekam RC. 2002. A locus for hereditary capillary malformations mapped on chromosome 5q. Hum Genet 110: 343-347.
20. Brouillard P, Boon LM, Mulliken JB, Enjolras O, Ghassibe M, Warman ML, TanOT, Olsen BR, Vikkula M. 2002. Mutations in a novel factor, glomulin, are responsible for glomuvenous malformations ("glomangiomas"). Am J Hum Genet 70: 866-874.
21. Brouillard P, Ghassibe M, Penington A, Boon LM, Dompmartin A, Temple IK, Cordisco M, Adams D, Piette F, Harper JI, et al. 2005. Four common glomulin mutations cause two thirds of glomuvenous malformations ("familial glomangiomas"): Evidence for a founder effect. J Med Genet 42: e13. 10. 1136/jmg. 2004. 024174.
22. Brouillard P, Enjolras O, Boon LM, Vikkula M. 2008. Glomulin and glomuvenous malformation. In Inborn errors of development, 2nd ed. (ed. Epstein CJ, et al.), pp. 1561-1565. Oxford University Press, Oxford.
23. Calvert JT, Riney TJ, Kontos CD, Cha EH, Prieto VG, Shea CR, Berg JN, Nevin NC, Simpson SA, Pasyk KA, et al. 1999. Allelic and locus heterogeneity in inherited venous malformations. Hum Mol Genet 8: 1279-1289.
24. Carmeliet P. 2005. VEGF as a key mediator of angiogenesis in cancer. Oncology 69: 4-10.
25. Carmeliet P, Ferreira V, Breier G, Pollefeyt S, Kieckens L, Gertsenstein M, FahrigM, Vandenhoeck A, Harpal K, Eberhardt C, et al. 1996. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature 380: 435-439.
26. Carver C, Brice G, Mansour S, Ostergaard P, Mortimer P, Jeffery S. 2007. Three children with Milroy disease and de novo mutations in VEGFR3. Clin Genet 71: 187-189.
27. Chambraud B, Radanyi C, Camonis JH, Shazand K, Rajkowski K, Baulieu EE. 1996. FAP48, a new protein that forms specific complexes with both immunophilins FKBP59 and FKBP12. Prevention by the immunosuppressant drugs FK506 and rapamycin. J Biol Chem 271: 32923-32929.
28. Chan AC, Drakos SG, Ruiz OE, Smith AC, Gibson CC, Ling J, Passi SF, StratmanAN, Sacharidou A, Revelo MP, et al. 2011. Mutations in 2 distinct genetic pathways result in cerebral cavernous malformations in mice. J Clin Invest 121: 1871-1881.
29. Chang J, Most D, Bresnick S, Mehrara B, Steinbrech DS, Reinisch J, LongakerMT, Turk AE. 1999. Proliferative hemangiomas: Analysis of cytokine gene expression and angiogenesis. Plast Reconstr Surg 103: 1-9.
30. Chen YG, Liu F, Massague J. 1997. Mechanism of TGFβ receptor inhibition by FKBP12. EMBO J 16: 3866-3876.
31. Chiller KG, Passaro D, Frieden IJ. 2002. Hemangiomas of infancy: Clinical characteristics, morphologic subtypes, and their relationship to race, ethnicity, and sex. Arch Dermatol 138: 1567-1576.
32. Cole SG, Begbie ME, Wallace GM, Shovlin CL. 2005. A new locus for hereditary haemorrhagic telangiectasia (HHT3) maps to chromosome 5. J Med Genet 42: 577-582.
33. Dale RF. 1985. The inheritance of primary lymphoedema. J Med Genet 22: 274-278.
34. D'Amato RJ, Loughnan MS, Flynn E, Folkman J. 1994. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci 91: 4082-4085.
35. Daniel-Spiegel E, Ghalamkarpour A, Spiegel R, Weiner E, Vikkula M, Shalev E, Shalev SA. 2005. Hydrops fetalis: An unusual prenatal presentation of hereditary congenital lymphedema. Prenat Diagn 25: 1015-1018.
36. David L, Mallet C, Mazerbourg S, Feige JJ, Bailly S. 2007. Identification of BMP9 and BMP10 as functional activators of the orphan activin receptor-like kinase 1 (ALK1) in endothelial cells. Blood 109: 1953-1961.
37. Dompmartin A, Acher A, Thibon P, Tourbach S, Hermans C, Deneys V, PocockB, Lequerrec A, Labbe D, Barrellier MT, et al. 2008. Association of localized intravascular coagulopathy with venous malformations. Arch Dermatol 144: 873-877.
38. Dompmartin A, Ballieux F, Thibon P, Lequerrec A, Hermans C, Clapuyt P, Barrellier MT, Hammer F, Labbe D, Vikkula M, et al. 2009. Elevated D-dimer level in the differential diagnosis of venous malformations. Arch Dermatol 145: 1239-1244.
39. Dompmartin A, Vikkula M, Boon LM. 2010. Venous malformation: Update on aetiopathogenesis, diagnosis and management. Phlebology 25: 224-235.
40. Dumont DJ, Gradwohl G, Fong GH, Puri MC, Gertsenstein M, Auerbach A, Breitman ML. 1994. Dominant-negative and targeted null mutations in the endothelial receptor tyrosine kinase, tek, reveal a critical role in vasculogenesis of the embryo. Genes Dev 8: 1897-1909.
41. Dumont DJ, Jussila L, Taipale J, Lymboussaki A, Mustonen T, Pajusola K, Breitman M, Alitalo K. 1998. Cardiovascular failure in mouse embryos deficient in VEGF receptor-3. Science 282: 946-949.
42. Eerola I, Boon LM, Watanabe S, Grynberg H, Mulliken JB, Vikkula M. 2002. Locus for susceptibility for familial capillary malformation ("port-wine stain") maps to 5q. Eur J Hum Genet 10: 375-380.
43. Eerola I, Boon LM, Mulliken JB, Burrows PE, Dompmartin A, Watanabe S, Vanwijck R, Vikkula M. 2003. Capillary malformation-arteriovenous malformation, a new clinical and genetic disorder caused by RASA1 mutations. Am J Hum Genet 73: 1240-1249.
44. Enjolras O, Breviere GM, Roger G, Tovi M, Pellegrino B, Varotti E, Soupre V, Picard A, Leverger G. 2004. Vincristine treatment for function-and life-threatening infantile hemangioma. Arch Pediatr 11: 99-107.
45. Fang J, Dagenais SL, Erickson RP, Arlt MF, Glynn MW, Gorski JL, Seaver LH, Glover TW. 2000. Mutations in FOXC2 (MFH-1), a forkhead family transcription factor, are responsible for the hereditary lymphedema-distichiasis syndrome. Am J Hum Genet 67: 1382-1388.
46. Ferrell RE, Kimak MA, Lawrence EC, Finegold DN. 2008. Candidate gene analysis in primary lymphedema. Lymphat Res Biol 6: 69-76.
47. Ferrell RE, Baty CJ, Kimak MA, Karlsson JM, Lawrence EC, Franke-Snyder M, Meriney SD, Feingold E, Finegold DN. 2010. GJC2 missense mutations cause human lymphedema. Am J Hum Genet 86: 943-948.
48. Finegold DN, Kimak MA, Lawrence EC, Levinson KL, Cherniske EM, Pober BR, Dunlap JW, Ferrell RE. 2001. Truncating mutations in FOXC2 cause multiple lymphedema syndromes. Hum Mol Genet 10: 1185-1189.
49. Finegold DN, Schacht V, Kimak MA, Lawrence EC, Foeldi E, Karlsson JM, BatyCJ, Ferrell RE. 2008. HGF and MET mutations in primary and secondary lymphedema. Lymphat Res Biol 6: 65-68.
50. Fong GH, Rossant J, Gertsenstein M, Breitman ML. 1995. Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium. Nature 376: 66-70.
51. Gale NW, Thurston G, Hackett SF, Renard R, Wang Q, McClain J, Martin C, WitteC, Witte MH, Jackson D, et al. 2002. Angiopoietin-2 is required for postnatal angiogenesis and lymphatic patterning, and only the latter role is rescued by Angiopoietin-1. Dev Cell 3: 411-423.
52. Gallione CJ, Repetto GM, Legius E, Rustgi AK, Schelley SL, Tejpar S, Mitchell G, Drouin E, Westermann CJ, Marchuk DA. 2004. A combined syndrome of juvenile polyposis and hereditary haemorrhagic telangiectasia associated with mutations in MADH4 (SMAD4). Lancet 363: 852-859.
53. Ghalamkarpour A, Morlot S, Raas-Rothschild A, Utkus A, Mulliken JB, Boon LM, Vikkula M. 2006. Hereditary lymphedema type I associated with VEGFR3 mutation: The first de novo case and atypical presentations. Clin Genet 70: 330-335.
54. Ghalamkarpour A, Devriendt K, Vikkula M. 2008. SOX18 and the hypotrichosis-lymphedema-telangiectasia syndrome. In Inborn errors of development, 2nd ed. (ed. Epstein CJ, et al.), pp. 913-915. Oxford University Press, Oxford.
55. Ghalamkarpour A, Debauche C, Haan E, Van Regemorter N, Sznajer Y, ThomasD, Revencu N, Gillerot Y, Boon LM, Vikkula M. 2009a. Sporadic in utero generalized edema caused by mutations in the lymphangiogenic genes VEGFR3 and FOXC2. J Pediatr 155: 90-93.
56. Ghalamkarpour A, Holnthoner W, Saharinen P, Boon LM, Mulliken JB, Alitalo K, Vikkula M. 2009b. Recessive primary congenital lymphoedema caused by a VEGFR3 mutation. J Med Genet 46: 399-404.
57. Glading A, Han J, Stockton RA, Ginsberg MH. 2007. KRIT-1/CCM1 is a Rap1 effector that regulates endothelial cell-cell junctions. J Cell Biol 179: 247-254.
58. Goodman TF, Abele DC. 1971. Multiple glomus tumors. A clinical and electron microscopic study. Arch Dermatol 103: 11-23.
59. Gottfried ON, Viskochil DH, Couldwell WT. 2010. Neurofibromatosis Type 1 and tumorigenesis: Molecular mechanisms and therapeutic implications. Neurosurg Focus 28: e8doi: 10. 3171/2009. 11. FOCUS09221.
60. Goumans MJ, Valdimarsdottir G, Itoh S, Rosendahl A, Sideras P, ten Dijke P. 2002. Balancing the activation state of the endothelium via two distinct TGF-β type I receptors. EMBO J 21: 1743-1753.
61. Govani FS, Shovlin CL. 2009. Hereditary haemorrhagic telangiectasia: A clinical and scientific review. Eur J Hum Genet 17: 860-871.
62. Greinwald JH Jr., Burke DK, Bonthius DJ, Bauman NM, Smith RJ. 1999. An update on the treatment of hemangiomas in children with interferon alfa-2a. Arch Otolaryngol Head Neck Surg 125: 21-27.
63. Grewal T, Evans R, Rentero C, Tebar F, Cubells L, de Diego I, Kirchhoff MF, Hughes WE, Heeren J, Rye KA, et al. 2005. Annexin A6 stimulates the membrane recruitment of pp120GAP to modulate Ras and Raf-1 activity. Oncogene 24: 5809-5820.
64. Grisendi S, Chambraud B, Gout I, Comoglio PM, Crepaldi T. 2001. Ligand-regulated binding of FAP68 to the hepatocyte growth factor receptor. J Biol Chem 276: 46632-46638.
65. Haggstrom AN, Drolet BA, Baselga E, Chamlin SL, Garzon MC, Horii KA, LuckyAW, Mancini AJ, Metry DW, Newell B, et al. 2007. Prospective study of infantile hemangiomas: Demographic, prenatal, and perinatal characteristics. J Pediatr 150: 291-294.
66. Hammill AM, Wentzel M, Gupta A, Nelson S, Lucky A, Elluru R, Dasgupta R, Azizkhan RG, Adams DM. 2011. Sirolimus for the treatment of complicated vascular anomalies in children. Pediatr Blood Cancer doi: 101002/pbc23124.
67. Hansen TM, Singh H, Tahir TA, Brindle NP. 2010. Effects of angiopoietins-1 and-2 on the receptor tyrosine kinase Tie2 are differentially regulated at the endothelial cell surface. Cell Signal 22: 527-532.
68. Harfouche R, Gratton JP, Yancopoulos GD, Noseda M, Karsan A, Hussain SN. 2003. Angiopoietin-1 activates both anti-and proapoptotic mitogen-activated protein kinases. FASEB J 17: 1523-1525.
69. Hayashi H, Kume T. 2008. Foxc transcription factors directly regulate Dll4 and Hey2 expression by interacting with the VEGF-Notch signaling pathways in endothelial cells. PLoS One 3: e2401. doi: 10. 1371/journal. pone. 0002401.
70. Hayashi H, Sano H, Seo S, Kume T. 2008. The Foxc2 transcription factor regulates angiogenesis via induction of integrin β3 expression. J Biol Chem 283: 23791-23800.
71. Henkemeyer M, Rossi DJ, Holmyard DP, Puri MC, Mbamalu G, Harpal K, ShihTS, Jacks T, Pawson T. 1995. Vascular system defects and neuronal apoptosis in mice lacking ras GTPase-activating protein. Nature 377: 695-701.
72. Hershkovitz D, Bergman R, Sprecher E. 2008. A novel mutation in RASA1 causes capillary malformation and limb enlargement. Arch Dermatol Res 300: 385-388.
73. Hogan BM, Bussmann J, Wolburg H, Schulte-Merker S. 2008. ccm1 cell autonomously regulates endothelial cellular morphogenesis and vascular tubulogenesis in zebrafish. Hum Mol Genet 17: 2424-2432.
74. Holland KE, Frieden IJ, Frommelt PC, Mancini AJ, Wyatt D, Drolet BA. 2010. Hypoglycemia in children taking propranolol for the treatment of infantile hemangioma. Arch Dermatol 146: 775-778.
75. Hu HT, Huang YH, Chang YA, Lee CK, Jiang MJ, Wu LW. 2008. Tie2-R849W mutant in venous malformations chronically activates a functional STAT1 to modulate gene expression. J Invest Dermatol 128: 2325-2333.
76. Irrthum A, Karkkainen MJ, Devriendt K, Alitalo K, Vikkula M. 2000. Congenital hereditary lymphedema caused by a mutation that inactivates VEGFR3 tyrosine kinase. Am J Hum Genet 67: 295-301.
77. Irrthum A, Devriendt K, Chitayat D, Matthijs G, Glade C, Steijlen PM, Fryns JP, Van Steensel MA, Vikkula M. 2003. Mutations in the transcription factor gene SOX18 underlie recessive and dominant forms of hypotrichosis-lymphedema-telangiectasia. Am J Hum Genet 72: 1470-1478.
78. Jacobs AH, Walton RG. 1976. The incidence of birthmarks in the neonate. Pediatrics 58: 218-222.
79. Jinnin M, Medici D, Park L, Limaye N, Liu Y, Boscolo E, Bischoff J, Vikkula M, Boye E, Olsen BR. 2008. Suppressed NFAT-dependent VEGFR1 expression and constitutive VEGFR2 signaling in infantile hemangioma. Nat Med 14: 1236-1246.
80. Johannessen CM, Reczek EE, James MF, Brems H, Legius E, Cichowski K. 2005. The NF1 tumor suppressor critically regulates TSC2 and mTOR. Proc Natl Acad Sci 102: 8573-8578.
81. Johnson DW, Berg JN, Baldwin MA, Gallione CJ, Marondel I, Yoon SJ, Stenzel TT, Speer M, Pericak-Vance MA, Diamond A, et al. 1996. Mutations in the activin receptor-like kinase 1 gene in hereditary haemorrhagic telangiectasia type 2. Nat Genet 13: 189-195.
82. Karkkainen MJ, Ferrell RE, Lawrence EC, Kimak MA, Levinson KL, McTigue MA, Alitalo K, Finegold DN. 2000. Missense mutations interfere with VEGFR-3 signalling in primary lymphoedema. Nat Genet 25: 153-159.
83. Karkkainen MJ, Saaristo A, Jussila L, Karila KA, Lawrence EC, Pajusola K, BuelerH, Eichmann A, Kauppinen R, Kettunen MI, et al. 2001. A model for gene therapy of human hereditary lymphedema. Proc Natl Acad Sci 98: 12677-12682.
84. Karnezis TT, Davidson TM. 2011. Efficacy of intranasal bevacizumab (Avastin) treatment in patients with hereditary hemorrhagic telangiectasia-associated epistaxis. Laryngoscope 121: 636-638.
85. Karpanen T, Wirzenius M, Makinen T, Veikkola T, Haisma HJ, Achen MG, Stacker SA, Pytowski B, Yla-Herttuala S, Alitalo K. 2006. Lymphangiogenic growth factor responsiveness is modulated by postnatal lymphatic vessel maturation. Am J Pathol 169: 708-718.
86. Khan ZA, Boscolo E, Picard A, Psutka S, Melero-Martin JM, Bartch TC, MullikenJB, Bischoff J. 2008. Multipotential stem cells recapitulate human infantile hemangioma in immunodeficient mice. J Clin Invest 118: 2592-2599.
87. Kidoya H, Ueno M, Yamada Y, Mochizuki N, Nakata M, Yano T, Fujii R, Takakura N. 2008. Spatial and temporal role of the apelin/APJ system in the caliber size regulation of blood vessels during angiogenesis. EMBO J 27: 522-534.
88. Kobayashi H, DeBusk LM, Babichev YO, Dumont DJ, Lin PC. 2006. Hepatocyte growth factor mediates angiopoietin-induced smooth muscle cell recruitment. Blood 108: 1260-1266.
89. Kontos CD, Stauffer TP, Yang WP, York JD, Huang L, Blanar MA, Meyer T, PetersKG. 1998. Tyrosine 1101 of Tie2 is the major site of association of pp85 and is required for activation of phosphatidylinositol 3-kinase and Akt. Mol Cell Biol 18: 4131-4140.
90. Korpelainen EI, Karkkainen M, Gunji Y, Vikkula M, Alitalo K. 1999. Endothelial receptor tyrosine kinases activate the STAT signaling pathway: Mutant Tie-2 causing venous malformations signals a distinct STAT activation response. Oncogene 18: 1-8.
91. Kriederman BM, Myloyde TL, Witte MH, Dagenais SL, Witte CL, Rennels M, Bernas MJ, Lynch MT, Erickson RP, Caulder MS, et al. 2003. FOXC2 haploinsufficient mice are a model for human autosomal dominant lymphedema-distichiasis syndrome. Hum Mol Genet 12: 1179-1185.
92. Kulkarni SV, Gish G, van der Geer P, Henkemeyer M, Pawson T. 2000. Role of p120 Ras-GAP in directed cell movement. J Cell Biol 149: 457-470.
93. Laberge-le Couteulx S, Jung HH, Labauge P, Houtteville JP, Lescoat C, CecillonM, Marechal E, Joutel A, Bach JF, Tournier-Lasserve E. 1999. Truncating mutations in CCM1, encoding KRIT1, cause hereditary cavernous angiomas. Nat Genet 23: 189-193.
94. Leaute-Labreze C, Dumas de la Roque E, Hubiche T, Boralevi F, Thambo JB, Taieb A. 2008. Propranolol for severe hemangiomas of infancy. N Engl J Med 358: 2649-2651.
95. Lebrin F, Goumans MJ, Jonker L, Carvalho RL, Valdimarsdottir G, Thorikay M, Mummery C, Arthur HM, ten Dijke P. 2004. Endoglin promotes endothelial cell proliferation and TGF-β/ALK1 signal transduction. EMBO J 23: 4018-4028.
96. Lebrin F, Srun S, Raymond K, Martin S, van den Brink S, Freitas C, Breant C, Mathivet T, Larrivee B, Thomas JL, et al. 2010. Thalidomide stimulates vessel maturation and reduces epistaxis in individuals with hereditary hemorrhagic telangiectasia. Nat Med 16: 420-428.
97. Limaye N, Wouters V, Uebelhoer M, Tuominen M, Wirkkala R, Mulliken JB, Eklund L, Boon LM, Vikkula M. 2009. Somatic mutations in angiopoietin receptor gene TEK cause solitary and multiple sporadic venous malformations. Nat Genet 41: 118-124.
98. Liquori CL, Berg MJ, Siegel AM, Huang E, Zawistowski JS, Stoffer T, Verlaan D, Balogun F, Hughes L, Leedom TP, et al. 2003. Mutations in a gene encoding a novel protein containing a phosphotyrosine-binding domain cause type 2 cerebral cavernous malformations. Am J Hum Genet 73: 1459-1464.
99. Liquori CL, Berg MJ, Squitieri F, Ottenbacher M, Sorlie M, Leedom TP, CannellaM, Maglione V, Ptacek L, Johnson EW, et al. 2006. Low frequency of PDCD10 mutations in a panel of CCM3 probands: Potential for a fourth CCM locus. Hum Mutat 27: 118.
100. Liu Y, Fang Y, Dong P, Gao J, Liu R, Hhahbaz M, Bi Y, Ding Z, Tian H, Liu Z. 2008. Effect of vascular endothelial growth factor C (VEGF-C) gene transfer in rat model of secondary lymphedema. Vascul Pharmacol 48: 150-156.
101. Mahmoud M, Allinson KR, Zhai Z, Oakenfull R, Ghandi P, Adams RH, FruttigerM, Arthur HM. 2010. Pathogenesis of arteriovenous malformations in the absence of endoglin. Circ Res 106: 1425-1433.
102. Maisonpierre PC, Suri C, Jones PF, Bartunkova S, Wiegand SJ, Radziejewski C, Compton D, McClain J, Aldrich TH, Papadopoulos N, et al. 1997. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science 277: 55-60.
103. Makinen T, Jussila L, Veikkola T, Karpanen T, Kettunen MI, Pulkkanen KJ, Kauppinen R, Jackson DG, Kubo H, Nishikawa S, et al. 2001. Inhibition of lymphangiogenesis with resulting lymphedema in transgenic mice expressing soluble VEGF receptor-3. Nat Med 7: 199-205.
104. Malik S, Grzeschik KH. 2008. Congenital, low penetrance lymphedema of lower limbs maps to chromosome 6q16. 2-q22. 1 in an inbred Pakistani family. Hum Genet 123: 197-205.
105. McAllister KA, Grogg KM, Johnson DW, Gallione CJ, Baldwin MA, Jackson CE, Helmbold EA, Markel DS, McKinnon WC, Murrell J, et al. 1994. Endoglin, a TGF-β binding protein of endothelial cells, is the gene for hereditary haemorrhagic telangiectasia type 1. Nat Genet 8: 345-351.
106. McIntyre BA, Brouillard P, Aerts V, Gutierrez-Roelens I, Vikkula M. 2004. Glomulin is predominantly expressed in vascular smooth muscle cells in the embryonic and adult mouse. Gene Expr Patterns 4: 351-358.
107. Mori Y, Sahara H, Matsumoto K, Takahashi N, Yamazaki T, Ohta K, Aoki S, Miura M, Sugawara F, Sakaguchi K, et al. 2008. Downregulation of Tie2 gene by a novel antitumor sulfolipid, 3′-sulfoquinovosyl-1′-monoacylglycerol, targeting angiogenesis. Cancer Sci 99: 1063-1070.
108. Morris PN, Dunmore BJ, Tadros A, Marchuk DA, Darland DC, D'Amore PA, Brindle NP. 2005. Functional analysis of a mutant form of the receptor tyrosine kinase Tie2 causing venous malformations. J Mol Med 83: 58-63.
109. Mosca L, Grady D, Barrett-Connor E, Collins P, Wenger N, Abramson BL, Paganini-Hill A, Geiger MJ, Dowsett SA, Amewou-Atisso M, et al. 2009. Effect of raloxifene on stroke and venous thromboembolism according to subgroups in postmenopausal women at increased risk of coronary heart disease. Stroke 40: 147-155.
110. Mulliken JB, Glowacki J. 1982. Hemangiomas and vascular malformations in infants and children: A classification based on endothelial characteristics. Plast Reconstr Surg 69: 412-422.
111. Nobuhara Y, Onoda N, Fukai K, Hosomi N, Ishii M, Wakasa K, Nishihara T, Ishikawa T, Hirakawa K. 2006. TIE2 gain-of-function mutation in a patient with pancreatic lymphangioma associated with blue rubber-bleb nevus syndrome: Report of a case. Surg Today 36: 283-286.
112. Oh SP, Seki T, Goss KA, Imamura T, Yi Y, Donahoe PK, Li L, Miyazono K, ten Dijke P, Kim S, et al. 2000. Activin receptor-like kinase 1 modulates transforming growth factor-β1 signaling in the regulation of angiogenesis. Proc Natl Acad Sci 97: 2626-2631.
113. O'Hagan AH, Moloney FJ, Buckley C, Bingham EA, Walsh MY, McKenna KE, McGibbon D, Hughes AE. 2006. Mutation analysis in Irish families with glomuvenous malformations. Br J Dermatol 154: 450-452.
114. Olson MF. 2008. Applications for ROCK kinase inhibition. Curr Opin Cell Biol 20: 242-248.
115. Park SO, Lee YJ, Seki T, Hong KH, Fliess N, Jiang Z, Park A, Wu X, Kaartinen V, Roman BL, et al. 2008. ALK5-and TGFBR2-independent role of ALK1 in the pathogenesis of hereditary hemorrhagic telangiectasia type 2. Blood 111: 633-642.
116. Park SO, Wankhede M, Lee YJ, Choi EJ, Fliess N, Choe SW, Oh SH, Walter G, Raizada MK, Sorg BS, et al. 2009. Real-time imaging of de novo arteriovenous malformation in a mouse model of hereditary hemorrhagic telangiectasia. J Clin Invest 119: 3487-3496.
117. Pennisi D, Bowles J, Nagy A, Muscat G, Koopman P. 2000a. Mice null for sox18are viable and display a mild coat defect. Mol Cell Biol 20: 9331-9336.
118. Pennisi D, Gardner J, Chambers D, Hosking B, Peters J, Muscat G, Abbott C, Koopman P. 2000b. Mutations in Sox18 underlie cardiovascular and hair follicle defects in ragged mice. Nat Genet 24: 434-437.
119. Petrova TV, Karpanen T, Norrmen C, Mellor R, Tamakoshi T, Finegold D, FerrellR, Kerjaschki D, Mortimer P, Yla-Herttuala S, et al. 2004. Defective valves and abnormal mural cell recruitment underlie lymphatic vascular failure in lymphedema distichiasis. Nat Med 10: 974-981.
120. Plummer NW, Gallione CJ, Srinivasan S, Zawistowski JS, Louis DN, Marchuk DA. 2004. Loss of p53 sensitizes mice with a mutation in Ccm1 (KRIT1) to development of cerebral vascular malformations. Am J Pathol 165: 1509-1518.
121. Plummer NW, Squire TL, Srinivasan S, Huang E, Zawistowski JS, Matsunami H, Hale LP, Marchuk DA. 2006. Neuronal expression of the Ccm2 gene in a new mouse model of cerebral cavernous malformations. Mamm Genome 17: 119-128.
122. Revencu N, Vikkula M. 2006. Cerebral cavernous malformation: New molecular and clinical insights. J Med Genet 43: 716-721.
123. Revencu N, Boon LM, Mulliken JB, Enjolras O, Cordisco MR, Burrows PE, ClapuytP, Hammer F, Dubois J, Baselga E, et al. 2008a. Parkes Weber syndrome, vein of Galen aneurysmal malformation, and other fast-flow vascular anomalies are caused by RASA1 mutations. Hum Mutat 29: 959-965.
124. Revencu N, Boon LM, Mulliken JB, Vikkula M. 2008b. RASA1 capillary malformation-arteriovenous malformation. In Inborn errors of development, 2nd ed. (ed. Epstein CJ, et al.), pp. 647-650. Oxford University Press, Oxford.
125. Riant F, Bergametti F, Ayrignac X, Boulday G, Tournier-Lasserve E. 2010. Recent insights into cerebral cavernous malformations: The molecular genetics of CCM. FEBS J 277: 1070-1075.
126. Rigamonti D, Hadley MN, Drayer BP, Johnson PC, Hoenig-Rigamonti K, KnightJT, Spetzler RF. 1988. Cerebral cavernous malformations. Incidence and familial occurrence. N Engl J Med 319: 343-347.
127. Rockson SG. 2008. Diagnosis and management of lymphatic vascular disease. J Am Coll Cardiol 52: 799-806.
128. Sato TN, Tozawa Y, Deutsch U, Wolburg-Buchholz K, Fujiwara Y, Gendron-Maguire M, Gridley T, Wolburg H, Risau W, Qin Y. 1995. Distinct roles of the receptor tyrosine kinases Tie-1 and Tie-2 in blood vessel formation. Nature 376: 70-74.
129. Seegar TC, Eller B, Tzvetkova-Robev D, Kolev MV, Henderson SC, Nikolov DB, Barton WA. 2010. Tie1-Tie2 interactions mediate functional differences between angiopoietin ligands. Mol Cell 37: 643-655.
130. Seki T, Hong KH, Oh SP. 2006. Nonoverlapping expression patterns of ALK1 and ALK5 reveal distinct roles of each receptor in vascular development. Lab Invest 86: 116-129.
131. Semones M, Feng Y, Johnson N, Adams JL, Winkler J, Hansbury M. 2007. Pyridinylimidazole inhibitors of Tie2 kinase. Bioorg Med Chem Lett 17: 4756-4760.
132. Serebriiskii I, Estojak J, Sonoda G, Testa JR, Golemis EA. 1997. Association of Krev-1/rap1a with Krit1, a novel ankyrin repeat-containing protein encoded by a gene mapping to 7q21-22. Oncogene 15: 1043-1049.
133. Shalaby F, Rossant J, Yamaguchi TP, Gertsenstein M, Wu XF, Breitman ML, Schuh AC. 1995. Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice. Nature 376: 62-66.
134. Shao ES, Lin L, Yao Y, Bostrom KI. 2009. Expression of vascular endothelial growth factor is coordinately regulated by the activin-like kinase receptors 1 and 5 in endothelial cells. Blood 114: 2197-2206.
135. Sirard C, de la Pompa JL, Elia A, Itie A, Mirtsos C, Cheung A, Hahn S, WakehamA, Schwartz L, Kern SE, et al. 1998. The tumor suppressor gene Smad4/Dpc4 is required for gastrulation and later for anterior development of the mouse embryo. Genes Dev 12: 107-119.
136. Srinivasan S, Hanes MA, Dickens T, Porteous ME, Oh SP, Hale LP, Marchuk DA. 2003. A mouse model for hereditary hemorrhagic telangiectasia (HHT) type 2. Hum Mol Genet 12: 473-482.
137. Stockton RA, Shenkar R, Awad IA, Ginsberg MH. 2010. Cerebral cavernous malformations proteins inhibit Rho kinase to stabilize vascular integrity. J Exp Med 207: 881-896.
138. Suri C, Jones PF, Patan S, Bartunkova S, Maisonpierre PC, Davis S, Sato TN, Yancopoulos GD. 1996. Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis. Cell 87: 1171-1180.
139. Suri C, McClain J, Thurston G, McDonald DM, Zhou H, Oldmixon EH, Sato TN, Yancopoulos GD. 1998. Increased vascularization in mice overexpressing angiopoietin-1. Science 282: 468-471.
140. Szuba A, Skobe M, Karkkainen MJ, Shin WS, Beynet DP, Rockson NB, Dakhil N, Spilman S, Goris ML, Strauss HW, et al. 2002. Therapeutic lymphangiogenesis with human recombinant VEGF-C. FASEB J 16: 1985-1987.
141. Taher TE, Derksen PW, de Boer OJ, Spaargaren M, Teeling P, van der Wal AC, Pals ST. 2002. Hepatocyte growth factor triggers signaling cascades mediating vascular smooth muscle cell migration. Biochem Biophys Res Commun 298: 80-86.
142. Takahashi K, Mulliken JB, Kozakewich HP, Rogers RA, Folkman J, Ezekowitz RA. 1994. Cellular markers that distinguish the phases of hemangioma during infancy and childhood. J Clin Invest 93: 2357-2364.
143. Tammela T, Saaristo A, Holopainen T, Lyytikka J, Kotronen A, Pitkonen M, Abo-Ramadan U, Yla-Herttuala S, Petrova TV, Alitalo K. 2007. Therapeutic differentiation and maturation of lymphatic vessels after lymph node dissection and transplantation. Nat Med 13: 1458-1466.
144. Therapontos C, Erskine L, Gardner ER, Figg WD, Vargesson N. 2009. Thalidomide induces limb defects by preventing angiogenic outgrowth during early limb formation. Proc Natl Acad Sci 106: 8573-8578.
145. Thomas G, Hall MN. 1997. TOR signalling and control of cell growth. Curr Opin Cell Biol 9: 782-787.
146. Uhlik MT, Abell AN, Johnson NL, Sun W, Cuevas BD, Lobel-Rice KE, Horne EA, Dell'Acqua ML, Johnson GL. 2003. Rac-MEKK3-MKK3 scaffolding for p38 MAPK activation during hyperosmotic shock. Nat Cell Biol 5: 1104-1110.
147. Valenzuela DM, Griffiths JA, Rojas J, Aldrich TH, Jones PF, Zhou H, McClain J, Copeland NG, Gilbert DJ, Jenkins NA, et al. 1999. Angiopoietins 3 and 4: Diverging gene counterparts in mice and humans. Proc Natl Acad Sci 96: 1904-1909.
148. Vikkula M, Boon LM, Carraway KL III., Calvert JT, Diamonti AJ, Goumnerov B, Pasyk KA, Marchuk DA, Warman ML, Cantley LC, et al. 1996. Vascular dysmorphogenesis caused by an activating mutation in the receptor tyrosine kinase TIE2. Cell 87: 1181-1190.
149. Vlahovic A, Simic R, Djokic D, Ceran C. 2009. Diffuse neonatal hemangiomatosis treatment with cyclophosphamide: A case report. J Pediatr Hematol Oncol 31: 858-860.
150. Voss K, Stahl S, Schleider E, Ullrich S, Nickel J, Mueller TD, Felbor U. 2007. CCM3 interacts with CCM2 indicating common pathogenesis for cerebral cavernous malformations. Neurogenetics 8: 249-256.
151. Voss K, Stahl S, Hogan BM, Reinders J, Schleider E, Schulte-Merker S, Felbor U. 2009. Functional analyses of human and zebrafish 18-amino acid in-frame deletion pave the way for domain mapping of the cerebral cavernous malformation 3 protein. Hum Mutat 30: 1003-1011.
152. Walter JW, Blei F, Anderson JL, Orlow SJ, Speer MC, Marchuk DA. 1999. Genetic mapping of a novel familial form of infantile hemangioma. Am J Med Genet 82: 77-83.
153. Whimster IW. 1976. The pathology of lymphangioma circumscriptum. Br J Dermatol 94: 473-486.
154. Whitehead KJ, Plummer NW, Adams JA, Marchuk DA, Li DY. 2004. Ccm1 is required for arterial morphogenesis: Implications for the etiology of human cavernous malformations. Development 131: 1437-1448.
155. Whitehead KJ, Chan AC, Navankasattusas S, Koh W, London NR, Ling J, MayoAH, Drakos SG, Jones CA, Zhu W, et al. 2009. The cerebral cavernous malformation signaling pathway promotes vascular integrity via Rho GTPases. Nat Med 15: 177-184.
156. Winnier GE, Hargett L, Hogan BL. 1997. The winged helix transcription factor MFH1 is required for proliferation and patterning of paraxial mesoderm in the mouse embryo. Genes Dev 11: 926-940.
157. Wouters V, Limaye N, Uebelhoer M, Irrthum A, Boon LM, Mulliken JB, EnjolrasO, Baselga E, Berg J, Dompmartin A, et al. 2010. Hereditary cutaneomucosal venous malformations are caused by TIE2 mutations with widely variable hyper-phosphorylating effects. Eur J Hum Genet 18: 414-420.
158. Wustehube J, Bartol A, Liebler SS, Brutsch R, Zhu Y, Felbor U, Sure U, AugustinHG, Fischer A. 2010. Cerebral cavernous malformation protein CCM1 inhibits sprouting angiogenesis by activating DELTA-NOTCH signaling. Proc Natl Acad Sci 107: 12640-12645.
159. Xue Y, Cao R, Nilsson D, Chen S, Westergren R, Hedlund EM, Martijn C, Rondahl L, Krauli P, Walum E, et al. 2008. FOXC2 controls Ang-2 expression and modulates angiogenesis, vascular patterning, remodeling, and functions in adipose tissue. Proc Natl Acad Sci 105: 10167-10172.
160. Yang XY, Guan M, Vigil D, Der CJ, Lowy DR, Popescu NC. 2009. p120Ras-GAP binds the DLC1 Rho-GAP tumor suppressor protein and inhibits its RhoA GTPase and growth-suppressing activities. Oncogene 28: 1401-1409.
161. Yuan HT, Khankin EV, Karumanchi SA, Parikh SM. 2009. Angiopoietin 2 is a partial agonist/antagonist of Tie2 signaling in the endothelium. Mol Cell Biol 29: 2011-2022.
162. Yue Y, Lypowy J, Hedhli N, Abdellatif M. 2004. Ras GTPase-activating protein binds to Akt and is required for its activation. J Biol Chem 279: 12883-12889.
163. Zawistowski JS, Stalheim L, Uhlik MT, Abell AN, Ancrile BB, Johnson GL, Marchuk DA. 2005. CCM1 and CCM2 protein interactions in cell signaling: Implications for cerebral cavernous malformations pathogenesis. Hum Mol Genet 14: 2521-2531.
164. Zhang J, Clatterbuck RE, Rigamonti D, Chang DD, Dietz HC. 2001. Interaction between krit1 and icap1α infers perturbation of integrin β1-mediated angiogenesis in the pathogenesis of cerebral cavernous malformation. Hum Mol Genet 10: 2953-2960.
165. Zhang L, Lin X, Wang W, Zhuang X, Dong J, Qi Z, Hu Q. 2005. Circulating level of vascular endothelial growth factor in differentiating hemangioma from vascular malformation patients. Plast Reconstr Surg 116: 200-204.